ArticleCureus2025
Assessment of Immunohistochemical Expression of Cluster of Differentiation 44 (CD44) in Breast Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cluster of differentiation 44 (CD44) expression in breast carcinoma is associated with basal-like epithelial markers in tumor cells, advanced tumor stage, and metaplastic variants. Since CD44 is a recently identified marker, further research is necessary to understand its immunoexpression and its relationship with hormone receptor status and other prognostic factors that influence patient management and therapy. This study was conducted to assess the expression of CD44 in breast cancer tissue. A cross-sectional investigation was conducted in our hospital on 60 mastectomy specimens received in the histopathology section of the Department of Pathology. The patient's age, tumor size, histological type, histological grade, and lymph node status were recorded. Immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PR ), human epidermal growth factor receptor 2/neu (HER2/neu), and CD44 markers was performed, and expression of CD44 was correlated with these clinicopathological and prognostic parameters. The results were subjected to statistical analysis. CD44 expression was detected in 51 of the 60 cases (85%). A statistically significant correlation was found between the expression of CD44 with patients' age, size of tumor, histological grade, and HER2/neu hormonal marker. No statistically significant relationship was observed between other factors, such as lymph node status and the expression of ER and PR. The expression of CD44 showed a strong correlation with known poor prognostic indicators, such as HER2/neu status and histological grade. Therefore, CD44 expression indicates an aggressive tumor biology and can serve as an independent marker for prognosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.